Published Studies Related to Timolol GFS (Timolol Ophthalmic)
Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus
bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or
ocular hypertension: a 12-week randomised controlled trial. 
hypertension... CONCLUSIONS: Bimatoprost/timolol PF demonstrated non-inferiority and equivalence
Effect of timolol on refractive outcomes in eyes with myopic regression after
laser in situ keratomileusis: a prospective randomized clinical trial. 
(length 4 to 8) was used for treatment allocation... CONCLUSIONS: Timolol application is effective for the treatment of myopic
Travoprost 0.004%/timolol 0.5%-fixed combination with and without benzalkonium chloride: a prospective, randomized, doubled-masked comparison of safety and efficacy. [2011.09]
PURPOSE: The purpose of this study is to compare the safety and intraocular pressure (IOP)-lowering efficacy of travoprost/timolol in a benzalkonium chloride (BAK)-free fixed combination preserved with polyquaternium-1 (TRA/TIM BAK-free), with travoprost/timolol-fixed combination preserved with BAK (TRA/TIM), in patients with open-angle glaucoma or ocular hypertension... CONCLUSION: Travoprost/timolol BAK-free demonstrated equivalence to travoprost/timolol preserved with BAK in efficacy. No clinically relevant differences in the safety profiles of travoprost/timolol BAK-free and travoprost/timolol preserved with BAK were identified.
Timolol versus brinzolamide added to travoprost in glaucoma or ocular hypertension. [2011.07]
BACKGROUND: To compare the efficacy and safety of timolol 0.5% versus brinzolamide 1.0% when added to travoprost monotherapy in patients with primary open-angle glaucoma or ocular hypertension... CONCLUSION: Both adjunctive combinations moderately reduced IOP in patients inadequately controlled with travoprost monotherapy, with timolol being slightly stronger 8 hours after instillation. Adjunctive treatment with brinzolamide and travoprost may be an alternative for patients not tolerant or not responsive to treatment with timolol and travoprost.
[Double-masked, phase III comparative study of the combination ophthalmic solution of the 1% dorzolamide hydrochloride/0.5% timolol maleate (MK-0507A) in patients with glaucoma and ocular hypertension]. [2011.06]
CONCLUSION: MK-0507A has a significantly superior IOP-lowering effect relative to timolol. MK-0507A also showed a non-inferior IOP-lowering effect relative to the concomitant therapy. MK-0507A was safe compared to both timolol and concomitant therapy.
Clinical Trials Related to Timolol GFS (Timolol Ophthalmic)
Pharmacokinetics, Safety and Tolerability of the Preservative-free Fixed Dose Combination of Tafluprost 0.0015% and Timolol 0.5% Eye Drops [Not yet recruiting]
Travoprost 0.004%/Timolol 0.5% Versus Timolol 0.5% in Chinese Patients With Open-Angle Glaucoma or Ocular Hypertension [Not yet recruiting]
Eligible patients will be randomized in a 1: 1 ratio to receive Travoprost 0. 004% / Timolol,
once daily or Timolol 0. 5%, twice-daily, for a total of twelve weeks. The study treatments
will be compared for mean intraocular pressure (IOP) change from baseline at Week 12.
Safety parameters measured at 3 study visits are : Ocular signs, visual acuity, dilated
fundus, cardiovascular parameters (blood pressure and pulse), and adverse events.
Timolol Option for Ulcerated Hemangiomas (TOUCH Trial) [Recruiting]
The purpose of this study is to determine whether Timolol 0. 5% Gel Forming Solution is safe
and effective in promoting wound healing of infantile ulcerated hemangiomas compared with
standard conservative management with topical antibiotic.
Topical Timolol for the Treatment of Benign Vascular Periocular Lesions [Recruiting]
The purpose of this research is to find out if the use of topical timolol 0. 5% solution
applied twice daily will help to shrink rosacea lesions around the eye.
Fixed Combination Brinzolamide 1%/Timolol 0.5% Versus Brinzolamide 1% + Timolol 0.5% in Open-angle Glaucoma or Ocular Hypertension [Recruiting]
Eligible patients will be randomized in a 1. 1 ratio to receive Brinzolamide 1%/Timolol 0. 5%
or Brinzolamide 1% plus Timolol 0. 5% two times a day for 8 Weeks. The study treatments will
be compared for mean diurnal intraocular pressure (IOP) change from baseline at Week 8.
Safety parameters measured at 4 study visits: ocular signs, visual acuity, cardiovascular
parameters (blood pressure and pulse), dilated fundus (entry and exit) and adverse events.